Buy 3 and get the 4th FREE!* | Learn More >>
12225
FLI1 Antibody
Primary Antibodies

FLI1 Antibody #12225

Reviews ()
Citations (0)

We recommend the following alternatives

# Product Name Application Reactivity
  • WB
  • IP
H M

Supporting Data

REACTIVITY
SENSITIVITY
MW (kDa) 52
SOURCE Rabbit

Application Key:

  • W-Western
  • IP-Immunoprecipitation
  • IHC-Immunohistochemistry
  • ChIP-Chromatin Immunoprecipitation
  • IF-Immunofluorescence
  • F-Flow Cytometry
  • E-P-ELISA-Peptide

Species Cross-Reactivity Key:

  • H-Human
  • M-Mouse
  • R-Rat
  • Hm-Hamster
  • Mk-Monkey
  • Mi-Mink
  • C-Chicken
  • Dm-D. melanogaster
  • X-Xenopus
  • Z-Zebrafish
  • B-Bovine
  • Dg-Dog
  • Pg-Pig
  • Sc-S. cerevisiae
  • Ce-C. elegans
  • Hr-Horse
  • All-All Species Expected

Storage:

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

FLI1 Antibody recognizes endogenous levels of total FLI1 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val64 of human FLI1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

Friend leukemia integration 1 (FLI1) transcription factor is an ETS domain-containing transcription factor that plays an important and highly conserved role in vertebrate development, particularly hematopoiesis, where it functions to activate transcription of genes that promote erythroblast proliferation (1-4). In mice, the Fli1 locus is a common retroviral insertion site for the Friend murine leukemia virus (F-MuLV), such that a majority of F-MuLV-induced erythroleukemias are associated with aberrant Fli1 expression (5). Notably in humans, aberrant FLI1 expression has also been linked to poor prognosis in acute myeloid leukemia (6). Also in humans, a t(11;22)(q24;q12) chromosomal translocation has been described that generates a chimeric protein (EWS/FLI1) comprised of the amino-terminal transactivation domain of Ewing's sarcoma breakpoint region 1 (EWS) and the carboxy-terminal ETS domain of FLI1 (7). The EWS/FLI1 fusion protein functions as a transcriptional activator that is reportedly responsible for >85% of the known cases of pediatric Ewing’s sarcoma, an aggressive bone and soft tissue tumor (8,9).

  1. Spyropoulos, D.D. et al. (2000) Mol Cell Biol 20, 5643-52.
  2. Pimanda, J.E. et al. (2007) Proc Natl Acad Sci U S A 104, 17692-7.
  3. Jagadeeswaran, P. et al. (2010) Blood Cells Mol Dis 44, 175-80.
  4. Tijssen, M.R. et al. (2011) Dev Cell 20, 597-609.
  5. Ben-David, Y. et al. (1990) Proc Natl Acad Sci U S A 87, 1332-6.
  6. Kornblau, S.M. et al. (2011) Blood 118, 5604-12.
  7. May, W.A. et al. (1993) Proc Natl Acad Sci U S A 90, 5752-6.
  8. Braun, B.S. et al. (1995) Mol Cell Biol 15, 4623-30.
  9. Riggi, N. and Stamenkovic, I. (2007) Cancer Lett 254, 1-10.

Pathways & Proteins

Explore pathways + proteins related to this product.

For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

To Purchase # 12225